

QUANTITY LIMIT CRITERIA

DRUG CLASS	ANTIEMETICS
BRAND NAME (generic)	ANZEMET (ALL DOSAGE FORMS) (dolasetron mesylate)
Status: CVS Caremark Criteria	
Type: Quantity Limit	

Policy

FDA-APPROVED INDICATIONS

Anzemet Tablets

Anzemet tablets are indicated for the prevention of nausea and vomiting associated with moderately emetogenic cancer chemotherapy, including initial and repeat courses in adults and children 2 years and older.

Anzemet Injection

Anzemet Injection is indicated for the following:

The prevention of postoperative nausea and vomiting (PONV) in adults and children 2 years and older.

As with other antiemetics, routine prophylaxis is not recommended for patients in whom there is little expectation that nausea and/or vomiting will occur postoperatively. In patients where nausea and/or vomiting must be avoided postoperatively, Anzemet Injection is recommended even where the incidence of postoperative nausea and/or vomiting is low. When prophylaxis has failed, a repeat dose should not be initiated as rescue therapy.

The treatment of postoperative nausea and/or vomiting in adults and children 2 years and older.

REFERENCES

1. Anzemet Tablets [package insert]. Parsippany, NJ: Validus Pharmaceuticals LLC; June 2016.
2. Anzemet Injection [package insert]. Bridgewater, NJ: sanofi-aventis U.S. LLC; October 2014.
3. AHFS DI (Adult and Pediatric) [database online]. Hudson, OH: Lexi-Comp, Inc.; http://online.lexi.com/lco/action/index/dataset/complete_ashp [available with subscription]. Accessed January 2018.
4. Micromedex Solutions [database online]. Greenwood Village, CO: Truven Health Analytics Inc. Updated periodically. www.micromedexsolutions.com [available with subscription]. Accessed January 2018.
5. Hesketh PJ, Bohlke K, Lyman GH, et al. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. *J Clin Onc* 33; 2015; 1-8.
6. National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Antiemesis. V.2.2017. Available at: www.nccn.org. Accessed January 2018.

Anzemet Limit Policy 01-2018

CVS Caremark is an independent company that provides pharmacy benefit management services to CareFirst BlueCross BlueShield and CareFirst BlueChoice, Inc. members.

CareFirst BlueCross BlueShield is the shared business name of CareFirst of Maryland, Inc. and Group Hospitalization and Medical Services, Inc. CareFirst of Maryland, Inc., Group Hospitalization and Medical Services, Inc., CareFirst BlueChoice, Inc., The Dental Network and First Care, Inc. are independent licensees of the Blue Cross and Blue Shield Association. In the District of Columbia and Maryland, CareFirst MedPlus is the business name of First Care, Inc. In Virginia, CareFirst MedPlus is the business name of First Care, Inc. of Maryland (used in VA by: First Care, Inc.). © Registered trademark of the Blue Cross and Blue Shield Association

LIMIT CRITERIA

Drug	4 Weeks Limit and 12 Weeks Limit*
Anzemet Tablets	6 tablets / 21 days
Anzemet Injection	15 mL / 6 months

**** This drug is indicated for short-term acute use; therefore, the mail limit will be the same as the retail limit. The duration of 21 days is used for a 28-day fill period.***